GSK 2239633A manufacturers
- GSK2239633A
-
- $32.00
-
2026-07-27
- CAS:1240516-71-5
- Purity: 99.82%
- Supply Ability: 10g
- GSK2239633A
-
- $32.00
-
2026-07-27
- CAS:1240516-71-5
- Purity: 99.82%
- Supply Ability: 10g
|
| | GSK 2239633A Basic information |
| Product Name: | GSK 2239633A | | Synonyms: | GSK 2239633A;Propanamide, N-[[3-[[3-[[(5-chloro-2-thienyl)sulfonyl]amino]-4-methoxy-1H-indazol-1-yl]methyl]phenyl]methyl]-2-hydroxy-2-methyl-;GSK-2239633A,inhibit,Inhibitor,CC chemokine receptor,CCR,GSK2239633A;N-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-4-(methyloxy)-1H-indazol-1-yl]methyl}phenyl)methyl]-2-hydroxy-2-methylpropanamide;GSK2239633A, 10 mM in DMSO | | CAS: | 1240516-71-5 | | MF: | C24H25ClN4O5S2 | | MW: | 549.06 | | EINECS: | | | Product Categories: | | | Mol File: | 1240516-71-5.mol |  |
| | GSK 2239633A Chemical Properties |
| density | 1.45±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO:152.46(Max Conc. mg/mL);277.67(Max Conc. mM) | | form | Solid | | pka | 7.03±0.30(Predicted) | | color | White to off-white | | InChIKey | YTEVTHHGQMUPHC-UHFFFAOYSA-N | | SMILES | C(NCC1=CC=CC(CN2C3=C(C(OC)=CC=C3)C(NS(C3SC(Cl)=CC=3)(=O)=O)=N2)=C1)(=O)C(O)(C)C |
| | GSK 2239633A Usage And Synthesis |
| Uses | GSK 2239633A, is an allosteric antagonist of human CCR4. | | in vivo | Following intravenous dosing, plasma GSK2239633A displays rapid, bi-phasic distribution and slow terminal elimination (t1/2: 13.5 hours), suggesting that GSK2239633A is a low to moderate clearance drug. Following oral dosing, blood levels of GSK2239633A reach Cmax rapidly (median tmax: 1.0-1.5 hours). Estimated GSK2239633A bioavailability is low with a maximum value determined of only 16%[1]. GSK2239633A (Compound 9) demonstrates good pharmacokinetic data in preclinical animal studies (bioavailability in rats and beagle dogs 85% and 97% respectively)[3]. | | IC 50 | [125I]-TARC-CCR4: 7.96 (pIC50) | | storage | Store at -20°C |
| | GSK 2239633A Preparation Products And Raw materials |
|